Upstream Bio Inc (UPB)

$9.50 +0.19 (2.04%)
Market Cap 516.99M
Revenue (ttm) 2.85M
Net Income (ttm) -143.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,032.98%
Debt to Equity Ratio 0.00
Volume 537,600
Avg Vol 1,473,860
Day's Range N/A - N/A
Shares Out 54.42M
Stochastic %K 60%
Beta 1.80
Analysts Strong Sell
Price Target $44.17

Company Profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 781 208 2466
Address:
890 Winter Street, Suite 200, Waltham, United States
StockConsultant
StockConsultant Mar. 26 at 2:26 PM
$UPB Upstream Bio stock, nice bottom breakout, from Stocks to Watch at https://stockconsultant.com/?UPB
0 · Reply
nikserr
nikserr Mar. 26 at 2:23 PM
$UPB I am out of UPB for now, I may get back in if it pulls back.
0 · Reply
nikserr
nikserr Mar. 26 at 2:02 PM
$UPB 32% Gain in no time !!
0 · Reply
nikserr
nikserr Mar. 26 at 1:57 PM
$UPB this happened in no time :)) My followers have made so much money already $JANX
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 26 at 12:18 PM
$UPB (+2.4% pre) Upstream Bio plans two late-stage trials for asthma, nasal polyps in 2027 https://ooc.bz/l/97306
0 · Reply
OwlKing
OwlKing Mar. 25 at 6:20 PM
$UPB $GV $ENGS $BNAI ^^3^
0 · Reply
Few_erish
Few_erish Mar. 25 at 4:37 PM
$UPB barely pulling back
0 · Reply
Jamminonfools
Jamminonfools Mar. 20 at 9:00 PM
$UPB anybody know why this jump up around .50 right before close?
0 · Reply
jd39
jd39 Mar. 19 at 1:29 PM
$UPB or maybe US$ 9
0 · Reply
Off_The_Top_Rope
Off_The_Top_Rope Mar. 18 at 9:24 PM
$UPB $12
0 · Reply
Latest News on UPB
Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data

Mar 26, 2026, 1:10 PM EDT - 8 days ago

Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 26, 2026, 7:00 AM EDT - 9 days ago

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Mar 1, 2026, 9:45 AM EST - 4 weeks ago

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Feb 26, 2026, 7:00 AM EST - 5 weeks ago

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Upstream Bio to Participate in Upcoming March Investor Conferences

Feb 25, 2026, 7:00 AM EST - 5 weeks ago

Upstream Bio to Participate in Upcoming March Investor Conferences

Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns

Feb 13, 2026, 10:45 AM EST - 7 weeks ago

Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns

Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Feb 11, 2026, 9:02 AM EST - 7 weeks ago

Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Feb 11, 2026, 6:00 AM EST - 7 weeks ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Feb 10, 2026, 6:00 PM EST - 7 weeks ago

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 3 months ago

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study

Dec 5, 2025, 4:48 PM EST - 4 months ago

Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study

Upstream Bio to Participate in Upcoming December Investor Conferences

Nov 25, 2025, 7:00 AM EST - 4 months ago

Upstream Bio to Participate in Upcoming December Investor Conferences

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Nov 5, 2025, 7:00 AM EST - 5 months ago

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio to Participate in Upcoming November Investor Conferences

Oct 31, 2025, 7:00 AM EDT - 5 months ago

Upstream Bio to Participate in Upcoming November Investor Conferences

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Sep 30, 2025, 4:15 AM EDT - 6 months ago

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 9, 2025, 7:00 AM EDT - 7 months ago

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio, Inc. - Special Call

Sep 7, 2025, 10:25 PM EDT - 7 months ago

Upstream Bio, Inc. - Special Call

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 2, 2025, 6:00 AM EDT - 7 months ago

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 1, 2025, 5:00 PM EDT - 7 months ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Aug 6, 2025, 7:00 AM EDT - 8 months ago

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Jul 8, 2025, 7:00 AM EDT - 9 months ago

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Jun 15, 2025, 7:45 AM EDT - 10 months ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Jun 5, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 20, 2025, 7:00 AM EDT - 11 months ago

Upstream Bio Appoints Stacy Price as Chief Technology Officer

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

May 6, 2025, 7:00 AM EDT - 11 months ago

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

Apr 17, 2025, 5:51 PM EDT - 1 year ago

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

3 Dividend Giants To Buy As Tariffs Hit Stocks

Mar 28, 2025, 3:56 PM EDT - 1 year ago

3 Dividend Giants To Buy As Tariffs Hit Stocks

PEP PG

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Upstream Bio to Present at Upcoming March Investor Conferences

Feb 25, 2025, 8:00 AM EST - 1 year ago

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Dec 16, 2024, 1:03 PM EST - 1 year ago

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Upstream Bio Announces Addition to Russell 2000® Index

Dec 16, 2024, 8:00 AM EST - 1 year ago

Upstream Bio Announces Addition to Russell 2000® Index

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Nov 5, 2024, 3:09 PM EST - 1 year ago

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Oct 11, 2024, 12:49 PM EDT - 1 year ago

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Upstream Bio raises $255 mln in US IPO

Oct 10, 2024, 7:42 PM EDT - 1 year ago

Upstream Bio raises $255 mln in US IPO

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Oct 10, 2024, 7:35 PM EDT - 1 year ago

Upstream Bio Announces Pricing of Upsized Initial Public Offering

StockConsultant
StockConsultant Mar. 26 at 2:26 PM
$UPB Upstream Bio stock, nice bottom breakout, from Stocks to Watch at https://stockconsultant.com/?UPB
0 · Reply
nikserr
nikserr Mar. 26 at 2:23 PM
$UPB I am out of UPB for now, I may get back in if it pulls back.
0 · Reply
nikserr
nikserr Mar. 26 at 2:02 PM
$UPB 32% Gain in no time !!
0 · Reply
nikserr
nikserr Mar. 26 at 1:57 PM
$UPB this happened in no time :)) My followers have made so much money already $JANX
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 26 at 12:18 PM
$UPB (+2.4% pre) Upstream Bio plans two late-stage trials for asthma, nasal polyps in 2027 https://ooc.bz/l/97306
0 · Reply
OwlKing
OwlKing Mar. 25 at 6:20 PM
$UPB $GV $ENGS $BNAI ^^3^
0 · Reply
Few_erish
Few_erish Mar. 25 at 4:37 PM
$UPB barely pulling back
0 · Reply
Jamminonfools
Jamminonfools Mar. 20 at 9:00 PM
$UPB anybody know why this jump up around .50 right before close?
0 · Reply
jd39
jd39 Mar. 19 at 1:29 PM
$UPB or maybe US$ 9
0 · Reply
Off_The_Top_Rope
Off_The_Top_Rope Mar. 18 at 9:24 PM
$UPB $12
0 · Reply
Cheaslea76
Cheaslea76 Mar. 18 at 8:04 PM
$UPB $6
0 · Reply
bababooey143
bababooey143 Mar. 17 at 9:16 PM
$UPB when is earnings?
0 · Reply
Gunnar1
Gunnar1 Mar. 17 at 4:37 PM
$UPB Took my gains at UPB, will watch it and potentially re-enter. According to Tradingview maybe earnings tomorrow...
0 · Reply
bababooey143
bababooey143 Mar. 17 at 3:06 PM
$UPB
0 · Reply
bababooey143
bababooey143 Mar. 16 at 11:04 PM
$UPB is that 58k a buy or a sell?
2 · Reply
bababooey143
bababooey143 Mar. 16 at 2:22 PM
$UPB
0 · Reply
bababooey143
bababooey143 Mar. 13 at 3:17 PM
$UPB should rebound here
0 · Reply
nikserr
nikserr Mar. 12 at 8:02 PM
$UPB Beautiful Chart!
0 · Reply
bababooey143
bababooey143 Mar. 12 at 7:46 PM
$UPB
0 · Reply
RocketCityRetai1
RocketCityRetai1 Mar. 12 at 4:43 AM
$IXHL now I have to mention $UPB once more. New bulls do DD. Oversold and climbing
0 · Reply
IntrepidLoad
IntrepidLoad Mar. 12 at 2:06 AM
$UPB having trouble valuing this one. I think need phase 3 data first which tells me is probably dropping first. But open to other opinions.
1 · Reply
IntraTrades
IntraTrades Mar. 11 at 10:44 PM
$UPB
0 · Reply